Zealand Pharma Revenue 2017-2021 | ZEAL

Zealand Pharma revenue from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Zealand Pharma Annual Revenue
(Millions of US $)
2020 $54
2019 $6
2018 $6
2017 $21
2016 $35
Zealand Pharma Quarterly Revenue
(Millions of US $)
2021-06-30 $14
2021-03-31 $8
2020-12-31 $11
2020-09-30 $9
2020-06-30 $33
2020-03-31 $2
2019-12-31 $2
2019-09-30 $1
2019-06-30 $3
2019-03-31
2018-12-31 $2
2018-09-30
2018-06-30 $2
2018-03-31 $2
2017-12-31 $2
2017-09-30 $6
2017-06-30 $2
2017-03-31 $11
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.494B $0.054B
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29